Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity
- 209 Downloads
Increased IFN-γ levels have been associated with systemic lupus erythematosus (SLE). However, the relationships among IFN-γ, type I interferons (IFNs) and clinical features have not been extensively studied. Peripheral blood samples from 44 SLE patients and 36 healthy donors (HDs) were collected. Quantitative real-time PCR was used to assess the mRNA expression of IFNG, type II IFN-inducible genes (IRF1, GBP1, CXCL9, CXCL10, and SERPING1, which are used for the type II IFN score), type I IFN-inducible genes (IRF7, MX1, ISG15, and ISG20, which are used for the type I IFN score), TBX21, and EOMES in peripheral blood mononuclear cells. Flow cytometry was used to measure the IFN-γ levels in lymphocytes. The mRNA levels of type II IFN-inducible genes, IFNG, TBX21, and EOMES were significantly higher in SLE patients than those in HDs. Similarly, the percentages of IFN-γ-producing cells in lymphocytes and their subsets in SLE patients were significantly increased. Linear regression indicated that IFNG expression levels and type II IFN scores were positively correlated with anti-double-stranded DNA autoantibody levels and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. Compared with patients with low type I IFN scores, patients with high type I IFN scores showed increased type II IFN scores and SLEDAI scores. Type II IFN scores were positively associated with type I IFN scores. The IFN-γ signaling pathway is activated in SLE patients and may be considered an index of disease activity. IFN-γ, together with type I IFNs, promotes the pathogenesis of SLE.
KeywordsDisease activity EOMES Interferon-gamma Interferon-inducible genes Systemic lupus erythematosus TBX21
This research was supported by the grants from the National Natural Science Foundation of China (31470854) and Pujiang Talents Plan (16PJ1405600).
National Natural Science Foundation of China (Grants No. 31470854) and Pujiang Talents Plan (Grants No. 16PJ1405600).
Compliance with ethical standards
The study was approved by the Ethics Committee of Xin Hua Hospital and was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
- 6.Huang X, Li J, Dorta-Estremera S, Di Domizio J, Anthony SM, Watowich SS, Popkin D, Liu Z, Brohawn P, Yao Y, Schluns KS, Lanier LL, Cao W (2015) Neutrophils regulate humoral autoimmunity by restricting interferon-gamma production via the generation of reactive oxygen species. Cell Rep 12(7):1120–1132. https://doi.org/10.1016/j.celrep.2015.07.021 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N, Rapp A, Steiner G, Scheinecker C, Smolen J, Aringer M (2009) Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 60(5):1463–1471. https://doi.org/10.1002/art.24449 CrossRefPubMedGoogle Scholar
- 10.Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E (2000) Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 122(3):464–470CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N (2008) Excessive production of IFN- in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 181(3):2211–2219. https://doi.org/10.4049/jimmunol.181.3.2211 CrossRefPubMedGoogle Scholar
- 14.Leng RX, Pan HF, Liu J, Yang XK, Zhang C, Tao SS, Wang DG, Li XM, Li XP, Yang W, Ye DQ (2016) Evidence for genetic association of TBX21 and IFNG with systemic lupus erythematosus in a Chinese Han population. Sci Rep 6:22081. https://doi.org/10.1038/srep22081 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 50(12):3958–3967. https://doi.org/10.1002/art.20798 CrossRefPubMedGoogle Scholar
- 17.Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, Utset TO, Jolly M, James JA, Harley JB, Niewold TB (2011) Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 63(4):1044–1053. https://doi.org/10.1002/art.30187 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC Jr, Kennedy WP (2016) A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 75(1):196–202. https://doi.org/10.1136/annrheumdis-2014-206090 CrossRefPubMedGoogle Scholar
- 22.Barkhouse DA, Garcia SA, Bongiorno EK, Lebrun A, Faber M, Hooper DC (2015) Expression of interferon gamma by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon. J Virol 89(1):312–322. https://doi.org/10.1128/JVI.01572-14 CrossRefPubMedGoogle Scholar
- 24.Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, Niewold TB, Tsokos GC, Keith MP, Harley JB, James JA (2016) Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 75(11):2014–2021. https://doi.org/10.1136/annrheumdis-2015-208140 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https://doi.org/10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y CrossRefPubMedGoogle Scholar
- 30.Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54(9):2951–2962. https://doi.org/10.1002/art.22044 CrossRefPubMedGoogle Scholar
- 31.Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debre P, Amoura Z, Vieillard V (2011) Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease. Arthritis Rheum 63(6):1698–1706. https://doi.org/10.1002/art.30313 CrossRefPubMedGoogle Scholar
- 32.Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya A, Latinis K, Chiu K, Oliner KS, Damore MA, Arnold GE, Sohn W, Chirmule N, Goyal L, Banfield C, Chung JB (2015) Blockade of interferon-gamma normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 67(10):2713–2722. https://doi.org/10.1002/art.39248 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Bhattacharyya S, Zhao Y, Kay TW, Muglia LJ (2011) Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci U S A 108(23):9554–9559. https://doi.org/10.1073/pnas.1017296108 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK (2014) Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther 16(1):R23. https://doi.org/10.1186/ar4451 CrossRefPubMedPubMedCentralGoogle Scholar